Teva-Barr addendum: Inasmuch as BRL was emerging as a serious contender in the FoB arena (based on its 2007 acquisition of Pliva), the TEVA-BRL deal reduces the number of FoB players by one.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”